Skip to main content
SpringerLink
Log in

Lacidipine

Aponil®, Caldine®, GR 43659, GR 43659X, GX 1048, Lacimen®, Lacipil®, Lacirex®, Midotens®, Motens®, SN 305, Viapres®

  • Research Review
  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Notes

  1. 1This profile has been selected from R&D Insight™, a pharmaceutical intelligence database produced by Adis International Ltd.

References

  1. Hall ST, Harding SM, Hassani H, Keene ON, Pellegatti M. The pharmacokinetic and pharmacodynamic interaction between lacidipine and propranolol in healthy volunteers. Journal of Cardiovascular Pharmacology 18 (Suppl 11): 13–17, 1991

    Article  Google Scholar 

  2. United Kingdom Lacidipine Study Group. A double-blind comparison of the efficacy and safety of lacidipine with atenolol in the treatment of essential hypertension. Journal of Cardiovascular Pharmacology 17 (Suppl 4): 27–30, 1991

    Google Scholar 

  3. Marone C, Weidmann P, Krontiris D, Marcolli M, Rizzini P. Acute antihypertensive efficacy of channel blockade with lacidipine, a new dihydropyridine. Current Therapeutic Research 50: 842–856, Dec 1991 Summary in 2 parts (Part A)

    Google Scholar 

  4. Leonetti G, Northern Italian Study Group of Lacidipine in Hypertension. Comparative study of lacidipine and nifedipine SR in the treatment of hypertension: an Italian multicenter study. Journal of Cardiovascular Pharmacology 17 (Suppl 4): 31–34, 1991

    Google Scholar 

  5. Nami R, Rizzini P, Buracchi P, Pavese G, Gennari C. Longterm antihypertensive treatment with lacidipine, a new longacting calcium antagonist. Journal of Cardiovascular Pharmacology 18 (Suppl 11): 22–25, 1991

    Article  Google Scholar 

  6. Zito M, Abate G, Cervone C, Squassante L, Calabrese G. Effects of antihypertensive therapy with lacidipine on ambulatory blood pressure in the elderly. Journal of Hypertension 9 (Suppl 3): 79–83, Dec 1991

    Google Scholar 

  7. Endersby CA, Brown EG, Perelman MS. Safety profile of lacidipine: a review of clinical data. Journal of Cardiovascular Pharmacology 17 (Suppl 4): 45–47, 1991

    Google Scholar 

  8. Forest Laboratories Inc. New Data on Investigational Hypertension Treatment, Lercanidipine, Presented at Ash Meeting. Media Release 15 May 2002. Available from URL: http://www.frx.com

    Google Scholar 

  9. Crosta L, Candiloro V, Meli M, et al. Lacidipine and josamycin: two new multidrug resistance modulators. Anticancer Research 14: 2685–2689, No. 6B, Nov–Dec 1994

    PubMed  CAS  Google Scholar 

  10. Heber ME, Broadhurst PA, Brigden GS, Raftery EB. Effectiveness of the once-daily calcium antagonist, lacidipine, in controlling 24-hour ambulatory blood pressure. American Journal of Cardiology 66: 1228–1232, 15 Nov 1990

    Article  PubMed  CAS  Google Scholar 

  11. Sheiban I, Arosio E, Montesi G, Tonni S, Montresor G, et al. Remodeling of left ventricular geometry and function induced by lacidipine and nifedipine SR in mild-to-moderate hypertension. Journal of Cardiovascular Pharmacology 17 (Suppl 4): 68–74, 1991

    Google Scholar 

  12. Morris AD, Donnelly R, Connell JMC, Reid JL. Metabolic effects of lacidipine: a placebo-controlled study using the euglycaemic hyperinsulinaemic clamp. British Journal of Clinical Pharmacology 35: 40–45, Jan 1993

    PubMed  CAS  Google Scholar 

  13. Dessì-Fulgheri P, Espinosa E, Zingaretti O, Guazzarotti F, Sarzani R, et al. Urinary kallikrein excretion and blood pressure response to angiotensin converting enzyme inhibitors and calcium antagonists in hypertensive patients. Journal of Hypertension 11: 725–730, Jul 1993

    Article  PubMed  Google Scholar 

  14. Lyons D, Fowler G, Webster J, Hall ST, Petrie JC. An assessment of lacidipine and atenolol in mild to moderate hypertension. British Journal of Clinical Pharmacology 37: 45–51, Jan 1994

    Article  PubMed  CAS  Google Scholar 

  15. Morris AD, Donnelly R, Connell JMC, Reid JL. Effects of the calcium antagonist lacidipine on insulin sensitivity in essential hypertension: a placebo-controlled study. Hormone and Metabolic Research 26: 257–259, May 1994

    Article  PubMed  CAS  Google Scholar 

  16. Wing LMH, Arnolda LF, Harvey PJ, Upton J, Molloy D, et al. Lacidipine, hydrochlorothiazide and their combination in systolic hypertension in the elderly. Journal of Hypertension 15: 1503–1510, Part 1, Dec 1997

    Article  PubMed  CAS  Google Scholar 

  17. Armas-Padilla MC, Armas-Hernández MJ, Hernández-Hernández R, Velasco M, Pacheco B, et al. Effect of lacidipine and nifedipine GITS on platelet function in patients with essential hypertension. Journal of Human Hypertension 14 (Suppl 1): 91–95, Apr 2000

    Article  Google Scholar 

  18. Chiariello M, Southern Italy Lacidipine Study Group. A double-blind comparison of the efficacy and safety of lacidipine and hydrochlorothiazide in essential hypertension. Journal of Cardiovascular Pharmacology 17 (Suppl 4): 35–37, 1991

    Google Scholar 

  19. Rizzini P, Castello C, Salvi S, Recchia G. Efficacy and safety of lacidipine, a new long-lasting calcium antagonist, in elderly hypertensive patients. Journal of Cardiovascular Pharmacology 17 (Suppl 4): 38–44, 1991

    Google Scholar 

  20. Palatini P, Penzo M, Guzzardi G, Anaclerio M, Pessina A. Ambulatory blood pressure monitoring in the assessment of antihypertensive treatment: 24-h blood pressure control with lacidipine once a day. Journal of Hypertension 9 (Suppl 3): 61–66, Dec 1991

    Google Scholar 

  21. Chaignon MM, Mourad J-J, Guédon J. Comparative effects of antihypertensive drugs on systolic blood pressure. Journal of Hypertension 11 (Suppl 1): S27–S31, Mar 1993

    Article  PubMed  CAS  Google Scholar 

  22. Yoshinaga K, Iimura O, Abe K, Saruta T, Yazaki Y, et al. Early phase II study of calcium channel blocker lacidipine (SN-305) in patients with essential hypertension: pilot study. Rinsho Iyaku 9: 2507–2521, No. 11, 1993

    Google Scholar 

  23. Kajiyama G, Hayashi K, Matsuura H, Oshima T, Takata K, et al. Clinical efficacy and effect on serum lipid and carbohydrate metabolism of lacidipine (SN-305) smaller tablet in essential hypertensive patients. Rinsho Iyaku 10: 1125–1141, No. 5, 1994

    Google Scholar 

  24. Spieker C, Zidek W. The impact of lacidipine, a novel dihydropyridine calcium antagonist, on carbohydrate and lipid metabolism. Journal of Cardiovascular Pharmacology 25 (Suppl 3): 23–26, 1995

    Google Scholar 

  25. Tcherdakoff P, The Investigators of Study LAC-05-91. French large-scale study evaluating the tolerability and efficacy of lacidipine. Journal of Cardiovascular Pharmacology 25 (Suppl 3): 27–32, 1995

    Google Scholar 

  26. Reyes AJ, Alcocer L, Velasco M, LASTLHY Group, et al. Lacidipine and nifedipine GITS as fixed-dose monopharmacotherapies in essential hypertension over sixteen weeks: main results of the LASTLHY. American Journal of Hypertension 11: 97, Part 2, Apr 1998

    Article  Google Scholar 

  27. Zanchetti A. Evaluating the benefits of an antihypertensive agent using trials based on event and organ damage: the Systolic Hypertension in the Elderly Long-term Lacidipine (SHELL) trial and the European Lacidipine Study on Atherosclerosis (ELSA). Journal of Hypertension 13 (Suppl 4): 35–39, Dec 1995

    Article  Google Scholar 

  28. Zanchetti A, Bond MG, Hennig M, ELSA Investigators, et al. Risk factors associated with alterations in carotid intimamedia thickness in hypertnesion: baseline data from the European Lacidipine Study on Atherosclerosis. Journal of Hypertension 16: 949–961, Jul 1998

    Article  PubMed  CAS  Google Scholar 

  29. Armas-Hernández MJ, Hernández-Hernández R, Armas-Padilla MC, Moreno-Castillo D, Guerrero J. Lacidipine on hypertension in association with lisinopril its effects on blood pressure and left ventricular mass. Journal of Hypertension 16 (Suppl 2): 243, Jun 1998

    Google Scholar 

  30. Van Montfrans GA, Schelling A, Buurke EJ, Schut N, Houben JJG. Dosing time of lacidipine and the circadian blood pressure curve: the MOTIME study. Journal of Hypertension 16 (Suppl 9): 15–19, Dec 1998

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lacidipine. Drugs R&D 3, 324–330 (2002). https://doi.org/10.2165/00126839-200203050-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200203050-00006

Keywords

Search

Navigation